Latest 10-K annual reports

Fossil Group reported a narrower net loss and improved gross margins in fiscal 2025, driven by its Turnaround Plan focusing on core traditional watches and cost structure optimization, despite declining net sales.

Village Farms International achieved significant financial improvements in 2025, driven by strong Canadian and Netherlands cannabis sales and strategic operational efficiencies.

KLX Energy Services Holdings, Inc. reported a significant increase in net loss for 2025 and amended its debt covenants to gain financial flexibility, extending its maximum net leverage ratio and clarifying equity cure options.

BJ's Wholesale Club announced increased net sales and net income for fiscal year 2025, driven by membership growth and strategic expansion, despite a slowdown in comparable club sales.

Centurion Acquisition Corp., a blank check company, reported a net income of $11.7 million for 2025, primarily from trust account interest, as it continues its search for a business combination by June 2026.

Mach Natural Resources LP reported significant increases in proved reserves and production volumes for 2025, driven by strategic acquisitions, despite a decline in net income due to impairment and debt extinguishment costs.

Smith Douglas Homes reported a decrease in net income and gross profit for 2025 amidst elevated mortgage rates, but increased new home orders and significantly expanded its controlled lot supply.

Universal Electronics Inc. reports a net loss of $18.6 million for fiscal year 2025, alongside a 6.7% revenue decline, as it continues strategic restructuring and focuses on climate control solutions.

Open Lending Corporation reported a net loss of $4.2 million for fiscal year 2025, a significant improvement from the prior year, driven by a positive profit share estimate adjustment and strategic cost-saving initiatives.

Korro Bio reports significant losses and a strategic shift in its AATD program after a clinical setback, while advancing its hyperammonemia candidate and securing new funding.

Allogene Therapeutics reports a $190.9 million net loss in 2025, advancing its allogeneic CAR T pipeline with key clinical milestones expected in 2026 and 2027, while managing operational risks and capital needs.

Citizens, Inc. announced a second consecutive year of total premium revenue growth in 2025, driven by domestic insurance sales and strategic initiatives, despite increased international endowment maturities.

OnKure Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and a going concern warning, despite advancing its lead cancer drug candidate, OKI-219, through Phase 1 trials with favorable preliminary safety data.

ACNB Corporation announced a 16.3% increase in net income to $37.1 million for 2025, primarily fueled by the acquisition of Traditions Bancorp, Inc. and strategic portfolio repositioning.

MariMed Inc. reports a 1.3% revenue increase in 2025, driven by wholesale growth and strategic acquisitions, while navigating evolving cannabis regulations and federal tax challenges.

Runway Growth Finance Corp. reports a decrease in net investment income and net assets for 2025, alongside strategic debt refinancings and a new joint venture, while its common stock trades at a significant discount to NAV.

CoastalSouth Bancshares, Inc. announced a 13.6% increase in net income to $24.9 million for 2025, alongside significant asset and loan growth, and declared its first quarterly cash dividend of $0.05 per share.

Resolute Holdings Management, Inc. reported a 10% increase in net sales for 2025, driven by domestic growth in its CompoSecure business, and completed the significant acquisition of Husky Technologies in early 2026.

Unusual Machines, Inc. announced significant revenue growth in its 2025 annual report, driven by expanding B2B sales and strategic acquisitions in the commercial drone industry.

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $105.4 million for 2025, while advancing its lead programs ORKA-001 and ORKA-002 in psoriasis and other inflammatory indications.

MVB Financial Corp. reported a significant increase in net income for 2025, driven by strategic divestitures and improved efficiency, despite a slight decline in net interest income.

DUKE Robotics Corp. reported increased revenues from its IC Drone services and initial royalties from defense systems in 2025, despite ongoing net losses and a going concern warning.

HeartBeam, Inc. reports significant progress in its 3D ECG technology with recent FDA clearances and initiates a limited market launch, despite ongoing concerns about its ability to continue as a going concern.

Eventbrite, the global live events marketplace, has been acquired by Bending Spoons for $4.50 per share in cash, ceasing to be a publicly traded company.

Kingsway Financial Services Inc. reports a net loss of $10.25 million in 2025, driven by increased operating expenses and acquisitions, while strategically expanding its Kingsway Search Xcelerator segment.

Inovio Pharmaceuticals reports a $84.9 million net loss for 2025 and faces substantial doubt about its ability to continue as a going concern, while its lead RRP candidate, INO-3107, encounters FDA questions on accelerated approval eligibility.

Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.

PAMT Corp reported a significant net loss of $52.6 million for fiscal year 2025, driven by declining revenues across its truckload and brokerage segments and a substantial increase in insurance and claims expenses.

Nephros, Inc. announced a significant increase in net income and revenue for fiscal year 2025, driven by higher programmatic sales and emergency response business, despite ongoing tariff impacts and an identified material weakness in internal controls.

Heritage Global Inc. reports a decline in net income and operating income for 2025, driven by a shift in revenue mix and significant nonaccrual loans in its Specialty Lending segment.